Lyell Immunopharma, Inc.
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer. Its lead programs, including ronde-cel (LYL314) and LYL273, are designed to improve durability and response rates in hematologic malignancies and solid tumors, while the company also operates its own manufacturing center to control supply and quality.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous cell therapies in clinical development for hematologic malignancies and solid tumors.
Internal cGMP manufacturing for patient-specific CAR T-cell products and viral vectors.
Technology development, translational research and manufacturing process optimization for pipeline assets.
Technology and asset access through acquisitions and license agreements that expand the pipeline.
Customers
Lyell does not yet sell approved commercial products; its current 'customers' are primarily clinical trial patients, investigators, hospitals and treatment centers participating in its studies. In the future, if approved, its therapies would be used by oncologists and specialty cancer centers treating relapsed/refractory lymphoma and metastatic colorectal cancer. The company also relies on partners, licensors and clinical sites to execute development and manufacturing transitions.
Patients with relapsed/refractory large B-cell lymphoma and advanced mCRC enrolled in trials to test safety and efficacy.
Hospitals and oncology centers that administer study treatment, monitor outcomes and support enrollment.
Specialty centers that would prescribe and infuse approved CAR T products if Lyell reaches commercialization.
Insurers and other payors that will determine access and adoption for premium-priced cell therapies.
Strategy
Lyell’s strategy is to build differentiated CAR T therapies with stronger potency and durability than first-generation products, starting with ronde-cel in large B-cell lymphoma and expanding into solid tumors with LYL273 and other programs. A central priority is to control manufacturing internally through LyFE, which is intended to improve supply reliability, reduce cost and protect proprietary process know-how. The company is also using acquisitions and licensing to broaden its pipeline and accelerate clinical development.
It is the lead asset and the main near-term value driver in LBCL.
Internal manufacturing is intended to reduce supply risk and improve economics.
Solid tumors broaden the addressable market beyond hematologic cancers.
Platform breadth can improve differentiation and support future partnerships or launches.
Geography
Lyell is headquartered and manufactures in the United States, with its LyFE Manufacturing Center in Bothell, Washington and a former West Hills facility that is being closed. The company’s disclosed operations are primarily U.S.-based, but its manufacturing design is intended to meet both U.S. and EU cGMP standards, supporting potential future international development and commercialization. Its LYL273 license excludes mainland China, Hong Kong, Macau and Taiwan, which creates a defined geographic boundary for that asset.
Risks
Lyell is a pre-revenue clinical-stage company, so its business depends on successful trial outcomes, regulatory approvals and access to capital. Its internal manufacturing strategy reduces some supply-chain risk but also concentrates execution risk in a single facility and in technology transfers for ronde-cel and LYL273. Competition is intense, and approved therapies may be difficult to displace without clearly superior clinical data and reimbursement support.
- Clinical development failureImpact: CriticalLikelihood: Medium
Lead assets are still in trials and may not show sufficient safety or efficacy.
Exposure - Manufacturing and supply disruptionImpact: HighLikelihood: Medium
Patient-specific CAR T production is complex and any transfer or quality issue can delay trials.
Exposure - Capital needs and dilutionImpact: HighLikelihood: Medium
The company has substantial losses and no commercial revenue to fund operations.
Exposure - Competitive pressureImpact: HighLikelihood: Medium
Approved CAR T therapies, bispecifics and other oncology drugs already have physician familiarity and payer coverage.
Exposure: LBCL and mCRC markets
- Integration and acquisition riskImpact: MediumLikelihood: Medium
ImmPACT and LYL273 integration may not deliver expected cost savings or pipeline benefits.
Exposure
Accounting
Judgemental itemsManagement accounts for the instrument at fair value through earnings, creating period-to-period volatility.
Impact: Can affect other income/expense and net loss
ImmPACT and LYL273 transactions require valuation of acquired assets, liabilities and contingent obligations.
Impact: Can affect goodwill/intangibles, amortization and future impairment risk
West Hills closure and workforce reduction may require severance and exit-related accruals.
Impact: Can affect operating expenses and cash outflows
Capitalized facility and equipment values depend on successful development and utilization.
Impact: Potential impairment charges if programs or capacity plans change
Similar listed companies
Publicly listed companies with a comparable business focus.
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Cabaletta Bio, Inc.
CABA · Biological Products, (No Diagnostic Substances)
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026